Earnings Call Summary | MaxCyte(MXCT.US) Q1 2024 Earnings Conference
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2024 Earnings Conference
The following is a summary of the MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript:
以下是MaxCyte, Inc.（MXCT）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
MaxCyte reported a total revenue of $11.3 million in Q1 2024, a rise of 32% from the $8.6 million reported for the same period in the previous year.
The company had a core revenue of $8.2 million, showing a 5% increase from Q1 2023's figures.
Instrument revenue disclosed at $1.9 million, Lease revenue at $2.6 million, and Processing Assembly revenue at $3.4 million.
The Specialized Licensed Programs (SPL) made $3.2 million in Q1 2024, a massive growth from just $0.8 million in Q1 2023.
MaxCyte foresees closing 2024 with at least $175 million in cash, cash equivalents, and investments without any debts.
MaxCyte報告稱，2024年第一季度的總收入爲1,130萬美元，較去年同期公佈的860萬美元增長了32％。
該公司的核心收入爲820萬美元，較2023年第一季度的數字增長了5％。
儀器收入披露爲190萬美元，租賃收入爲260萬美元，加工裝配收入爲340萬美元。
專業許可項目（SPL）在2024年第一季度的收入爲320萬美元，較2023年第一季度的80萬美元大幅增長。
MaxCyte預計，到2024年底，將有至少1.75億美元的現金、現金等價物和沒有任何債務的投資。
Business Progress:
業務進展：
MaxCyte finalized 4 new SPLs in 2024, expanding the total number of SPLs to 27, thus projecting its continued importance to cell and gene innovators.
MaxCyte has invested in R&D expenses, customer support, technological abilities, and recruitment of field application scientists.
CASGEVY approved in multiple geographies, leading to solidifying the company's position in the non-viral cell therapies market.
While maintaining balance sheet health, the company has sighted substantial growth opportunities for 2024.
In order to stay ahead, MaxCyte is allocating extra resources aligning their interests with their partners.
The pipeline for future Specialized Licensed Programs is looking healthy, despite not speculating on signing any additional ones in the current year.
Actively involved in corporate development efforts, looking at opportunities for organic and inorganic growth.
Working with a wider array of cell therapies, MaxCyte anticipates the field to continue evolving and get more complex.
MaxCyte在2024年敲定了4個新的SPL，將SPL的總數擴大到27個，從而預示了其對細胞和基因創新者的持續重要性。
MaxCyte已投資於研發費用、客戶支持、技術能力和現場應用科學家的招聘。
CASGEVY在多個地區獲得批准，鞏固了該公司在非病毒細胞療法市場的地位。
在保持資產負債表健康的同時，該公司看到了2024年的巨大增長機會。
爲了保持領先地位，MaxCyte正在分配額外資源，使他們的利益與合作伙伴保持一致。
儘管沒有猜測在本年度還會簽署任何其他專業許可項目，但未來的專業許可項目的籌劃渠道看起來不錯。
積極參與企業發展工作，尋找有機和無機增長的機會。
與更廣泛的細胞療法合作，MaxCyte預計該領域將繼續發展並變得更加複雜。
More details: MaxCyte IR
更多詳情： maxCyte 紅外
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。